Category - News

Markets

Mackie ups Bellus Health PT to $2.20 from $1

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

November 20, 2018

Developments

IntelGenx gains media attention for VersaFilm delivery of cannabis

The Canada Pot Talks radio show has interviewed Horst Zerbe, president and CEO of IntelGenx (TSXV:IGX; OTCQX:IGXT), about its partnership with Tilray (NASDAQ:TLRY) to co-develop and commercializean IntelGenx VersaFilm...

November 20, 2018

Developments

Canopy Growth affiliate receives Health Canada cannabis license

Canopy Rivers’ (TSXV:RIV) portfolio company, Radicle Medical Marijuana, received a production and sales licence from Health Canada to supply and sell finished cannabis products for both the medical and adult-use market...

November 19, 2018

Markets

Leerink starts Assembly Biosciences at OP; PT $45

Leerink Partners launched coverage of Assembly Biosciences (NASDAQ:ASMB) with an “outperform” rating and $45 price target. The stock closed at $24.67 on Nov. 16. “Our valuation and rating are based on our probability...

November 19, 2018

Executive Moves

Richard Gormley joins HCW as vice chairman, president of capital markets

Richard Gormley has joined investment bank, H.C. Wainwright, as vice chairman and president of capital markets. Mr. Gormley has over 30 years of experience in the investment banking and capital markets business, having...

November 19, 2018

Markets

A.G.P./Alliance ups Titan Pharma PT to 65 cents from 45 cents

A.G.P./ Alliance Global Partners raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to 65 cents from 45 cents after the company’s third quarter results exceeded forecasts. The stock closed at 40 cents on...

November 16, 2018

Markets

Leerink starts AC Immune at OP; PT $18

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

November 16, 2018

Markets

Leerink starts Adamas Pharma at OP; PT $20

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

November 16, 2018

Markets

Leerink starts Intra-Cellular Therapies at OP; PT $27

Leerink Partners initiated coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with an “outperform” rating and $27 price target. The stock closed at $15.86 on Nov. 14. Intra-Cellular is focused on development of...

November 15, 2018

Markets

Leerink ups Mersana Therapeutics to OP; holds PT at $14

Leerink Partners upgraded Mersana Therapeutics (NASDAQ:MRSN) to “outperform” from “market perform” but maintained its price target of $14, citing the stock’s valuation. It closed at $6.04 on Nov. 13. “We are upgrading...

November 14, 2018

Category - News

Subscribe